Phase I study of intrathecal rituximab in patients with recurrent CNS [central nervous system] lymphoma.

Trial Profile

Phase I study of intrathecal rituximab in patients with recurrent CNS [central nervous system] lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrial.gov record.
    • 01 Oct 2012 Planned end date 1 Jun 2013 added as reported by ClinicalTrials.gov.
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top